<DOC>
	<DOCNO>NCT01458249</DOCNO>
	<brief_summary>The purpose study evaluate efficacy safety eribulin mesylate subject soft tissue sarcoma receive least one standard chemotherapy ( anthracycline ifosfamide monotherapy combination therapy ) .</brief_summary>
	<brief_title>An Open-label , Multicenter , Phase 2 Study Evaluate Efficacy Safety Eribulin Mesylate Previously Treated Subjects With Advanced Metastatic Soft Tissue Sarcoma ( Study E7389-J081-217 )</brief_title>
	<detailed_description />
	<mesh_term>Sarcoma</mesh_term>
	<criteria>Inclusion Criteria Histologically cytologically confirm soft tissue sarcoma high intermediate grade Documented evidence advance metastatic soft tissue sarcoma , amenable surgery radiotherapy Within 6 month radiographic evidence disease progression RECIST criterion last chemotherapy regimen advance metastatic soft tissue sarcoma Presence measurable disease Response Evaluation Criteria Solid Tumors ( RECIST ) 1.1 Subjects receive least one standard chemotherapy advance soft tissue sarcoma ( anthracycline ifosfamide monotherapy , combination therapy ) Subjects age ≥ 20 year time inform consent Eastern Cooperative Oncology Group ( ECOG ) performance status ( PS ) 0 1 Adequate organ function Voluntary agreement provide write informed consent Exclusion Criteria A history malignancy recurrence within 5 year remission Significant cardiovascular impairment Any serious concomitant illness infection require treatment . Hypersensitivity either halichondrin B halichondrin B chemical derivative . Subjects previously participate study eribulin ( whether treat eribulin ) . Any medical condition , opinion principal investigator , preclude participation clinical trial . Subjects received anticancer therapy , include surgery , radiotherapy , immunotherapy , cytotoxic , hormonal , biological ( include humanize antibody ) target agent within 21 day , investigational agent within 30 day , prior first dose study drug . Subjects recover toxicity result prior anticancer therapy ≤ Grade 1 , accord Common Terminology Criteria Adverse Events ( CTCAE ) , except peripheral neuropathy Grade 2 alopecia . Subjects know cerebral metastasis clinical symptom require treatment . Preexisting peripheral neuropathy &gt; CTCAE Grade 2 . Female subject must pregnant negative pregnancy test Screening , breastfeed . Subjects participate clinical trial</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>Soft Tissue Sarcoma</keyword>
</DOC>